Grifols addresses Canada license suspension. Grifols stock gains 1.04 percent.

Grifols said on September 24, 2026, that a Canada plasma license suspension had no impact, as MarketScreener reported, citing Reuters. Grifols stock was trading at EUR 9.67 at Lang & Schwarz on October 1, 2026 at 2:09 p.m. CEST, up 1.04 percent versus the EUR 9.57 prior close.

Canada license issue stays contained

The September 24 statement addressed a regulatory issue involving one of Grifols' Canadian plasma licenses. The company said the suspension would not affect operations, making the announcement a direct test of the market's sensitivity to supply and collection risks.

That backdrop matters because plasma-derived products account for 86.2 percent of Grifols' sales, according to the company profile carried by MarketScreener. The concentration gives operational updates on plasma collection unusual weight for the investment case.

Profit grows faster than revenue

Grifols reported EUR 3.574 billion of revenue in the first half of 2026, an increase of 2.60 percent at constant currency. The figure came alongside adjusted EBITDA of EUR 854 million and a 23.90 percent adjusted EBITDA margin, according to Grifols.

Net profit rose 28.70 percent year over year to EUR 227 million in the same period. Free cash flow before mergers and acquisitions reached EUR 91 million, an improvement of EUR 103 million from the first half of 2025, while net leverage stood at 4.20 times, Quartr reported in its October 1, 2026 earnings summary.

Cash flow remains the key measure

Management confirmed full-year 2026 guidance, including free cash flow before mergers and acquisitions of EUR 500 million to EUR 575 million. The first-half result therefore puts the company at 16.52 percent to 18.20 percent of the lower and upper guidance range, respectively, leaving execution and cash conversion as the central measures for the rest of 2026.

Immunoglobulin revenue grew 5.40 percent at constant currency in the first half, while albumin performance in China was expected to stabilize in the second half. That contrast explains why profitability and cash flow provide a clearer near-term read-through than revenue alone.

Grifols stock trades above prior close

At Lang & Schwarz, Grifols stock was trading at EUR 9.67 on October 1, 2026 at 2:09 p.m. CEST, up 1.04 percent from the EUR 9.57 prior close of September 30, 2026. The primary listing is BME under ticker GRF, while the company is classified in the pharmaceuticals sector.

The further course of trading is shown by the continuously updated real-time quote of Grifols stock.

More news and analyses on Grifols stock